Iñaki F Trocóniz Selected Research

1- (N(2)- (3,4- dibromo- N- ((4- (3,4- dihydro- 2(1H)- oxoquinazolin- 3- yl)- 1- piperidinyl)carbonyl)tyrosyl)lysyl)- 4- (4- pyridinyl)piperazine

1/2006	Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.
7/2004	Population pharmacokinetic modelling of BIBN 4096 BS, the first compound of the new class of calcitonin gene-related peptide receptor antagonists.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Iñaki F Trocóniz Research Topics

Disease

22	Neoplasms (Cancer) 10/2021 - 04/2004
6	Neutropenia 01/2020 - 09/2010
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 01/2008
3	Infections 02/2019 - 01/2008
3	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2008
2	Acute Intermittent Porphyria (Porphyria, Acute) 01/2022 - 11/2019
2	Melanoma (Melanoma, Malignant) 01/2020 - 11/2016
2	Urinary Tract Infections (Urinary Tract Infection) 01/2020 - 02/2019
2	Prostatic Neoplasms (Prostate Cancer) 01/2018 - 09/2012
2	Parkinson Disease (Parkinson's Disease) 01/2017 - 12/2002
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 04/2016 - 01/2016
2	Disease Progression 02/2016 - 06/2015
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 06/2015 - 05/2014
2	Surgical Wound Infection 05/2015 - 05/2012
2	Critical Illness (Critically Ill) 01/2014 - 01/2008
2	Renal Insufficiency (Renal Failure) 01/2014 - 01/2008
2	Nausea 06/2013 - 08/2012
2	Pain (Aches) 12/2012 - 09/2006
2	Acromegaly 04/2012 - 01/2009
2	Hyperalgesia 01/2010 - 08/2008
2	Erectile Dysfunction 06/2007 - 08/2004
2	Migraine Disorders (Migraine) 01/2006 - 07/2004
1	Rare Diseases (Rare Disease) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Multiple Myeloma 01/2022
1	Triple Negative Breast Neoplasms 01/2020
1	Inflammation (Inflammations) 01/2019
1	Stomach Neoplasms (Stomach Cancer) 01/2019
1	Hematologic Neoplasms (Hematological Malignancy) 01/2019
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2018
1	Bipolar Disorder (Manic Depressive Psychosis) 12/2016
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 10/2016
1	Respiratory Insufficiency (Respiratory Failure) 03/2016
1	Drug-Related Side Effects and Adverse Reactions 02/2016
1	Acoustic Neuroma (Acoustic Neurinoma) 01/2016
1	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2016
1	Body Weight (Weight, Body) 05/2015

Drug/Important Bio-Agent (IBA)

16	Pharmaceutical PreparationsIBA 01/2022 - 10/2011
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2014
4	Propofol (Diprivan)FDA LinkGeneric 01/2017 - 12/2002
4	lanreotide (Somatuline)FDA Link 04/2016 - 01/2009
2	Cetuximab (Erbitux)FDA Link 01/2022 - 01/2020
2	EnzymesIBA 01/2022 - 06/2007
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2013
2	Immune Checkpoint InhibitorsIBA 10/2021 - 01/2019
2	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2020 - 02/2019
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2020 - 05/2014
2	Cefuroxime (Zinacef)FDA LinkGeneric 02/2019 - 05/2015
2	Testosterone (Sustanon)FDA Link 01/2018 - 09/2012
2	Triptorelin Pamoate (Trelstar)FDA Link 01/2018 - 09/2012
2	Remifentanil (Ultiva)FDA Link 03/2016 - 06/2013
2	diflomotecanIBA 07/2015 - 10/2011
2	lumiracoxib (prexige)IBA 12/2012 - 01/2010
2	Delayed-Action PreparationsIBA 09/2012 - 06/2009
2	BI 2536IBA 12/2011 - 09/2010
2	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 03/2010 - 04/2004
2	Topotecan (Hycamtin)FDA LinkGeneric 03/2010 - 04/2004
2	Tadalafil (Cialis)FDA Link 06/2007 - 08/2004
2	1- (N(2)- (3,4- dibromo- N- ((4- (3,4- dihydro- 2(1H)- oxoquinazolin- 3- yl)- 1- piperidinyl)carbonyl)tyrosyl)lysyl)- 4- (4- pyridinyl)piperazineIBA 01/2006 - 07/2004
1	ParaproteinsIBA 01/2022
1	Hydroxymethylbilane Synthase (Porphobilinogen Deaminase)IBA 01/2022
1	AntigensIBA 10/2021
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	Busulfan (Busulfex)FDA Link 01/2020
1	InterferonsIBA 01/2020
1	treosulfanIBA 01/2020
1	Phenobarbital (Luminal)FDA Link 11/2019
1	Aminolevulinic Acid (Levulan)FDA Link 11/2019
1	Heme (Haem)IBA 11/2019
1	AlbuminsIBA 01/2019
1	Glycoproteins (Glycoprotein)IBA 01/2019
1	RNA Polymerase II (RNA Polymerase B)IBA 01/2019
1	C-Reactive ProteinIBA 01/2019
1	PM 01183IBA 01/2019
1	Dexmedetomidine FDA Link 01/2017
1	LithiumIBA 12/2016
1	Monoclonal AntibodiesIBA 11/2016
1	Hormones (Hormone)IBA 04/2016
1	TOR Serine-Threonine KinasesIBA 01/2016
1	Bevacizumab (Avastin)FDA Link 01/2016
1	Liposomes (Liposome)IBA 01/2016
1	Everolimus FDA Link 01/2016
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2016
1	Chromogranin AIBA 01/2016
1	Epidermal Growth Factor (EGF)IBA 01/2016
1	Vascular Endothelial Growth FactorsIBA 01/2016
1	ElementsIBA 07/2015
1	Metronidazole (Metric)FDA LinkGeneric 05/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 05/2015

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 01/2022 - 04/2004
5	Therapeutics 01/2020 - 09/2010
2	Neoadjuvant Therapy 01/2019 - 01/2019
2	Analgesia 03/2016 - 08/2008
2	Continuous Renal Replacement Therapy 01/2014 - 01/2008
1	Immunotherapy 10/2021
1	Intravenous Administration 01/2019
1	Deep Brain Stimulation 01/2017
1	Subcutaneous Injections 04/2016
1	Precision Medicine 06/2015